photo of jonathan riess taken from health.ucdavis.edu
Aug 28, 2024, 19:52
Impact of baseline positive vs negative plasma Circulating tumor DNA for Estimated glomerular filtration rate in the FLAURA2 trial by Jonathan Riess
David Gandara, Co-Director-Center for Experimental Therapeutics, shared a post on X:
“At Cal Cancer Consortium conference, Jonathan Riess shows impact of baseline positive vs negative plasma Circulating tumor DNA for Estimated glomerular filtration rate in the FLAURA2 trial.
Addition of chemo to Osi mainly benefitting those with positive Circulating tumor DNA .
Food for thought!”
Source: David Gandara/X